Recovering scientist turned early stage VC A biotech optimist fighting gravity

Confessions Of A Planner
April 3, 2020

This blog was written by Samantha Truex, CEO of Quench Bio, as part of the From The Trenches feature of LifeSciVC.  I am a planner.  I like to plan most things well in advance; in fact, maybe too far in

Leave a comment

The Balancing Act: Taking A Systematic Approach To Hard Decisions In Times Of Rapid Change
March 30, 2020

This blog was written by Ankit Mahadevia, CEO of Spero Therapeutics, as part of the From The Trenches feature of LifeSciVC.  If CEOs have empowered their teams effectively, they have three roles during times of rapid change: Motivator in chief

Leave a comment

Strategic Planning In Biotech During A Pandemic Crisis
March 26, 2020

In the throes of a full COVID-19 pandemic, most business leaders’ top priority is rightfully the health and safety of their employees, families, and communities. Even though business disruptions are significant and overwhelming, the primary efforts focused on both safety

Leave a comment

Recipe For Managing Data Disclosure Successfully With Academic Partners: A Public Gene Therapy Company Perspective
March 24, 2020

This blog post was written by Deanna Petersen, CBO of AVROBIO, as part of the From The Trenches feature of LifeSciVC. When AVROBIO went public in June 2018, I found myself on the steep end of an unexpected but interesting

Leave a comment

Coming Together While Staying Apart
March 23, 2020

This blog was written by Aoife Brennan, CEO of Synlogic, as part of the From The Trenches feature of LifeSciVC. I have never participated in trench warfare and I am sure it was pretty grim for those who lived and

Leave a comment

Core (Values) Workout
March 5, 2020

This blog was written by Jeb Keiper, CEO of Nimbus Therapeutics LLC, as part of the From The Trenches feature of LifeSciVC. Like many middle-aged weekend warriors, I’ve been recently sidelined by injury simply through doing what I’ve regularly done:

Leave a comment

BioPharma M&A Drives More Efficient Resource Allocation
March 2, 2020

M&A is an omnipresent reality in the biopharma industry, from Big Pharma mega-mergers to smaller acquisitions of emerging startups. We’ve recently witnessed several large M&A transactions get closed or announced, including BMS-Celgene, Takeda-Shire, and AbbVie-Allergan; according to BMO Capital Markets

Leave a comment

Call Me, Maybe
February 3, 2020

This blog post was written by Aoife Brennan, CEO of Synlogic, as part of the From The Trenches feature of LifeSciVC. My first job at a public company was when I joined Biogen or Biogen Idec as it was then

Leave a comment

Wither New Biotech Startups?
January 27, 2020

Biotech is in the midst of an incredible era of innovation: new modalities and novel medicines delivering real value to patients, leading to a decade-long bull cycle. It’s been exhilarating to watch and participate in this market, and venture capital

Leave a comment

Kyn to Ikena: The Art and Science of Rebranding
December 17, 2019

This blog was written by Mark Manfredi, CEO of Ikena Oncology, and guest blogger Maude Tessier, CBO, as part of the From The Trenches feature of LifeSciVC. When we started to think about changing our company name, we knew it

Leave a comment

Our 2019 Year In Review: Macro, Biotech, and Atlas
December 13, 2019

It’s that time of year again when we pause to reflect on the state of the industry – and there’s more to focus on in biopharma today than just the drug pricing debate. As I described last year, we host

Leave a comment

Venturing A Perspective On The Drug Pricing Debate
December 10, 2019

The perennial drug pricing debate has reached a fever pitch, as loud as it’s ever been over the past few decades. Politicians on both sides are bashing the drug industry with the typical talking points about exorbitant prices, countered of

Leave a comment